BECOME A MEMBER

Get my in-depth research reports about the most interesting investments in the world

Please fill out the form below

Price: USD 49/year

(Please note that I do not offer refunds; this is a recurring subscription that you can cancel at any time up to 15 days before your renewal date).

As an Annual Member you'll have access to:

  • 10 extensive research reports (PDF format) each year
  • Archive with all past research reports
  • Updates on previous research reports
  • Email alerts for reports and updates

Do you want to enjoy even more benefits, such as additional investment opportunities or priority booking of reader events and trips? Sign up for a Lifetime Membership.

Do you want to pay by cheque, cash or bank transfer? Would you like to purchase a gift voucher? Please send me a message.

Tax-deductible invoices can be downloaded from your account after sign-up.

 

Most recent

More Weekly Dispatches

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.

All reports